Research progress on iodinated contrast encephalopathy
10.3760/cma.j.cn114015-20210705-00746
- VernacularTitle:碘对比剂脑病的研究进展
- Author:
Aibin GUO
1
;
Rong YIN
Author Information
1. 甘肃省中医药大学第一临床医学院研究生院，兰州 730099
- Publication Type:Journal Article
- Keywords:
Contrast media;
Brain diseases;
Neurotoxicity syndromes;
Drug-related side effects and adverse reactions
- From:
Adverse Drug Reactions Journal
2021;23(12):639-643
- CountryChina
- Language:Chinese
-
Abstract:
Iodinated contrast encephalopathy is a rare complication after angiography or interventional therapy with iodinated contrast medium (ICM), with an incidence of 0.13%-2.92%. Iodinated contrast encephalopathy usually occurs minutes to hours after the use of ICM. Its clinical manifestations are diverse, and transient cortical blindness is the most common. Most patients have a good prognosis and generally recover completely within 48-72 hours, while a few may have irreversible neurological damage. The pathogenesis of iodinated contrast encephalopathy is not clear, which may be related to high-dose exposure of ICM due to the damage of blood-brain barrier and the direct cytotoxicity of ICM. Previous history of chronic kidney disease and stroke are risk factors for iodinated contrast encephalopathy, and types of ICM and body parts of angiography or intervention may have different influence on it. After angiography or interventional treatment using ICM, whether patients have symptoms such as mental disorder, visual field defect, and epilepsy should be observed. Once suspicious symptoms appear, CT or magnetic resonance imaging should be completed in time to avoid delaying treatment.
